Get the Stockscreener App
2.43
58.82%
0.90
Pre-market:
2.68
0.25
+10.29%
Pepgen Inc stock is traded at $2.43, with a volume of 24.69M.
It is up +58.82% in the last 24 hours and up +30.65% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$1.53
Open:
$1.51
24h Volume:
24.69M
Relative Volume:
10.36
Market Cap:
$79.44M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.8182
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
+68.75%
1M Performance:
+30.65%
6M Performance:
-74.61%
1Y Performance:
-84.18%
1-Day Range:
$1.50
$2.53
1-Week Range:
$1.345
$4.48
52-Week Range:
$1.16
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
2.43 | 79.44M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.50 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.78 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.70 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.10 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
278.38 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
What is HC Wainwright’s Estimate for PepGen FY2025 Earnings? - Defense World
Wedbush Weighs in on PepGen’s Q1 Earnings (NASDAQ:PEPG) - Defense World
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable
Stock market news: Binah Capital Group +184.15%, PepGen +35.25% among top gainers during midday trading - Business Upturn
Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments - TipRanks
What is HC Wainwright’s Estimate for PepGen Q1 Earnings? - Defense World
PepGen CFO Noel Donnelly sells $2,565 in stock By Investing.com - Investing.com South Africa
PepGen general counsel DeLena sells $2,405 in stock - Investing.com India
PepGen general counsel DeLena sells $2,405 in stock By Investing.com - Investing.com South Africa
PepGen CFO Noel Donnelly sells $2,565 in stock - Investing.com India
Biotech Alert: Searches spiking for these stocks today - TipRanks
PepGen reports positive initial data from Phase I DM1 therapy trial - MSN
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen Inc. Reports Positive Trial Results and Financials - TipRanks
PepGen (NASDAQ:PEPG) Receives “Buy” Rating from HC Wainwright - Defense World
Sell Rating on PepGen Inc. Amid Clinical and Regulatory Challenges - TipRanks
What's Driving the Market Sentiment Around PepGen? - Benzinga
PepGen stock price target cut to $14 by Stifel analysts - Investing.com Australia
Pepgen rallies as early data suggest sporting chance in DM1 - BioWorld Online
PepGen Drug Shows Signs of Topping Rivals in Rare Muscle Disease With No Approved Meds - MedCity News
Biotech Stock PepGen Inc. (NASDAQ: PEPG) Makes NASDAQ Top Gainers List on Financial Results and Update - Investorideas.com newswire
Stock market news: AtlasClear Holdings +282.98%, PepGen +109.42% among top gainers during midday trading - Business Upturn
PepGen Inc. Announces Positive FREEDOM-DM1 Trial Results - MSN
Promising Initial Data and Safety Profile Boost PepGen’s FREEDOM-DM1 Trial Outlook - TipRanks
PepGen data ‘very encouraging’ for program, says H.C. Wainwright - TipRanks
Why PepGen (PEPG) Stock Is Skyrocketing Today - Benzinga
Stock market today: AtlasClear Holdings +318.09%, PepGen +151.82% among top gainers in early trading - Business Upturn
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -February 24, 2025 at 07:01 am EST - Marketscreener.com
PepGen initial DM1 data ‘a clear win,’ says Stifel - TipRanks
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 - BioSpace
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights - Business Wire
PepGen reports promising DM1 drug trial results - Investing.com
PepGen announces initial clinical data from cohorts in FREEDOM-DM1 trial - TipRanks
PepGen Inc. SEC 10-K Report - TradingView
Can PepGen's 29% Splicing Success Transform DM1 Treatment? Key Trial Data Revealed - StockTitan
PepGen stock plunges to 52-week low at $1.16 amid market challenges - MSN
Taking on analysts’ expectations and winning: PepGen Inc (PEPG) - SETE News
PEPG’s 2023 Market Dance: Down -64.64% – Time to Invest? - The InvestChronicle
why PepGen Inc [PEPG] is a Good Choice for Investors After New Price Target of $12.80 - The DBT News
FY2029 Earnings Estimate for PepGen Issued By HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
Market Update: PepGen Inc (PEPG) Sees Negative Movement, Closing at 1.25 - The Dwinnex
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $16.00 - MarketBeat
H.C. Wainwright cuts PepGen stock target to $16, maintains Buy rating - Investing.com India
JPMorgan Chase & Co. Increases Holdings in PepGen Inc. (NASDAQ:PEPG) - Defense World
HC Wainwright Lowers PepGen (NASDAQ:PEPG) Price Target to $16.00 - Defense World
PepGen price target lowered to $16 from $26 at H.C. Wainwright - Yahoo Finance
PepGen stock plunges to 52-week low of $1.76 amid market challenges - Investing.com
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):